DK1264840T3 - Langtidsvirkende fusionspeptidinhibitorer af viral infektion - Google Patents

Langtidsvirkende fusionspeptidinhibitorer af viral infektion

Info

Publication number
DK1264840T3
DK1264840T3 DK02014617T DK02014617T DK1264840T3 DK 1264840 T3 DK1264840 T3 DK 1264840T3 DK 02014617 T DK02014617 T DK 02014617T DK 02014617 T DK02014617 T DK 02014617T DK 1264840 T3 DK1264840 T3 DK 1264840T3
Authority
DK
Denmark
Prior art keywords
long
viral infection
fusion peptide
peptide inhibitors
peptides
Prior art date
Application number
DK02014617T
Other languages
English (en)
Inventor
Dominique P Bridon
Robert P Dufresne
Nissab Boudjellab
Martin Robitaille
Peter G Milner
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26832297&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1264840(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of DK1264840T3 publication Critical patent/DK1264840T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK02014617T 1999-05-17 2000-05-17 Langtidsvirkende fusionspeptidinhibitorer af viral infektion DK1264840T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10
PCT/US2000/013651 WO2000069902A1 (en) 1999-05-17 2000-05-17 Long lasting fusion peptide inhibitors or viral infection

Publications (1)

Publication Number Publication Date
DK1264840T3 true DK1264840T3 (da) 2009-11-16

Family

ID=26832297

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02014617T DK1264840T3 (da) 1999-05-17 2000-05-17 Langtidsvirkende fusionspeptidinhibitorer af viral infektion

Country Status (14)

Country Link
US (4) US7582301B1 (da)
EP (3) EP2110381A1 (da)
JP (3) JP4216480B2 (da)
CN (1) CN1351611A (da)
AT (2) ATE443714T1 (da)
AU (1) AU761591B2 (da)
BR (1) BR0010757A (da)
CA (1) CA2372338A1 (da)
DE (2) DE60000665T3 (da)
DK (1) DK1264840T3 (da)
ES (2) ES2334106T3 (da)
HK (1) HK1053128A1 (da)
PT (1) PT1264840E (da)
WO (1) WO2000069902A1 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
AU761591B2 (en) * 1999-05-17 2003-06-05 Conjuchem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US7741453B2 (en) 2001-05-31 2010-06-22 Conjuchem Biotechnologies, Inc. Long lasting fusion peptide inhibitors for HIV infection
AU2002314111A1 (en) 2001-06-15 2003-01-02 F. Hoffmann-La Roche Ag Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
NZ539539A (en) * 2002-09-24 2006-11-30 Frontier Biotechnologies Co HIV gp41 c-terminal peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
ES2411962T3 (es) 2003-10-24 2013-07-09 Gencia Corporation Métodos y composiciones para suministrar polinucleótidos
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
PT2100904E (pt) * 2004-04-23 2010-09-24 Conjuchem Biotechnologies Inc Fase sólida para utilização num método para a purificação de conjugados de albumina
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种***的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
ES2381631T3 (es) 2006-02-02 2012-05-30 Synageva Biopharma Corp. Péptidos inhibidores de la fusión del VIH con propiedades biológicas mejoradas
CN100366633C (zh) * 2006-04-18 2008-02-06 河北师范大学 棕点湍蛙抗病毒多肽及其在制药中的应用
CA2658474A1 (en) 2006-08-17 2008-02-21 F.Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
CA2687700A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
CN101835801B (zh) 2007-08-08 2014-09-10 诺维信生物制药丹麦公司 转铁蛋白变体和偶联物
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
KR101435953B1 (ko) * 2009-07-17 2014-09-02 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
RU2013113723A (ru) 2010-09-14 2014-10-20 Ф.Хоффманн-Ля Рош Аг Гибридный полипептид с серпиновым "пальцем"
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
EP3501550A1 (en) 2012-04-02 2019-06-26 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2013150532A1 (en) 2012-04-04 2013-10-10 Yeda Research And Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
EP2981334A4 (en) * 2013-04-03 2016-11-23 Univ California COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
CN103864921B (zh) * 2014-01-16 2017-12-26 苏州大学 双重靶向治疗癌症的叶酸‑阿霉素免疫制剂及其制备方法
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
KR20180101341A (ko) 2015-11-10 2018-09-12 비스테라, 인크. 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
JP2020500306A (ja) 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
AU2018209940A1 (en) 2017-01-18 2019-07-11 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
CN116710146A (zh) 2020-04-03 2023-09-05 威特拉公司 抗体分子-药物偶联物及其用途
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
JPH06509551A (ja) 1991-04-05 1994-10-27 ジェネンテク，インコーポレイテッド Ｇｐ　ＩＩ↓ｂＩＩＩ↓ａに対する高い特異性を有する血小板凝集阻害剤
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
KR100358209B1 (ko) 1992-07-20 2003-01-24 듀크 유니버시티 Hiv복제를저해하는조성물
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
ATE381948T1 (de) 1995-05-10 2008-01-15 Kyowa Hakko Kogyo Kk Cytotoxinkonjugate umfassend dipeptide
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4086936B2 (ja) 1996-10-03 2008-05-14 株式会社ブリヂストン ダミーウェハ
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
JP2001522863A (ja) * 1997-11-07 2001-11-20 コンジュケム，インコーポレーテッド Ｒｇｄ含有ペプチドおよび内因性担体の新規コンジュゲート
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
IL133053A0 (en) 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
MXPA01003770A (es) * 1998-10-13 2002-05-06 Univ Georgia Res Found Peptidos bioactivos estabilizados, y metodos de identificacion, sintesis y uso de los mismos.
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
AU761591B2 (en) 1999-05-17 2003-06-05 Conjuchem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US7741453B2 (en) 2001-05-31 2010-06-22 Conjuchem Biotechnologies, Inc. Long lasting fusion peptide inhibitors for HIV infection
PT2100904E (pt) * 2004-04-23 2010-09-24 Conjuchem Biotechnologies Inc Fase sólida para utilização num método para a purificação de conjugados de albumina
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target

Also Published As

Publication number Publication date
DE60043021D1 (de) 2009-11-05
PT1264840E (pt) 2010-01-04
CA2372338A1 (en) 2000-11-23
JP4216480B2 (ja) 2009-01-28
EP1264840B1 (en) 2009-09-23
DE60000665D1 (de) 2002-11-28
BR0010757A (pt) 2002-02-19
JP2009167208A (ja) 2009-07-30
ES2185595T3 (es) 2003-05-01
JP2002544287A (ja) 2002-12-24
ATE226593T1 (de) 2002-11-15
EP1179012B2 (en) 2009-07-15
HK1053128A1 (en) 2003-10-10
EP1179012B9 (en) 2003-09-10
US20080199483A1 (en) 2008-08-21
ATE443714T1 (de) 2009-10-15
DE60000665T3 (de) 2009-10-29
EP2110381A1 (en) 2009-10-21
EP1179012A1 (en) 2002-02-13
EP1264840A1 (en) 2002-12-11
US20050070475A1 (en) 2005-03-31
CN1351611A (zh) 2002-05-29
EP1179012B1 (en) 2002-10-23
DE60000665T2 (de) 2003-06-26
JP2008101021A (ja) 2008-05-01
US20080176794A1 (en) 2008-07-24
US7608271B2 (en) 2009-10-27
ES2185595T5 (es) 2009-12-17
ES2334106T3 (es) 2010-03-05
US7582301B1 (en) 2009-09-01
AU5027100A (en) 2000-12-05
AU761591B2 (en) 2003-06-05
WO2000069902A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
DK1264840T3 (da) Langtidsvirkende fusionspeptidinhibitorer af viral infektion
ATE252601T1 (de) Lang wirkende insulinotrope peptide
EA200701386A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
LU92175I2 (fr) Lixisénatide
ATE380822T1 (de) Funf-helix protein
HK1154874A1 (en) Pegylated interleukin-10 -10
FI933740A (fi) PEG-interferonkonjugat
NO20014857D0 (no) Makrocykliske peptider aktive mot Hepatitt C virus
TR200002179T2 (tr) Kristalin teriparatid.
CU23048A3 (es) Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
ATE425188T1 (de) Physiologisch wirksames polypeptidkonjugat mit verlängerter in vivo halbwertszeit
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE463260T1 (de) Ortspezifische duale pegylation von proteine
NO20022229D0 (no) Hemoglobinpreparater med reduserte bivirkninger
ATE490969T1 (de) Modifizierte transferrin-fusionsproteine
DE69901726D1 (de) Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
EP1185545A4 (en) CD4-INDEPENDENT HIV ENVELOPE PROTEINS AS VACCINE AND THERAPEUTICA
WO2004076474A3 (en) Polyethylene glycol modified interferon compositions and methods of use thereof
ES2156731A1 (es) Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
DE60045663D1 (de) Rlichem interferon-alpha
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao